Obesity already costs the UK 126bn a year and is projected to rise even further
For all clinical questions, please consult your medical provider.
Table 1 Basic information of main active substances
This science-backed method revolves around activating key arousal pathways with an FDA-approved peptide: PT-141 (bremelanotide), commonly known as the "Pink Shot." It addresses hypoactive sexual desire disorder (HSDD) by stimulating brain receptors involved in sexual motivation, leading to increased desire, better lubrication, heightened sensitivity, reduced pain during intercourse, and greater overall satisfactionwithout directly altering hormones.[1][2][3] Clinical trials show it can significantly improve sexual function scores in premenopausal women with HSDD, with up to 51% reporting enhanced desire compared to placebo groups, but its benefits extend to perimenopausal and postmenopausal women dealing with vaginal atrophy and low libido.[1] Weve long known that peptides can influence sexual health, but PT-141 stands out as the first FDA-approved injectable specifically for HSDD in women
As healthcare systems focus on preventive measures and effective treatment options for these chronic conditions, the demand for GLP-1 receptor agonists is expected to grow, driving market expansion
.jpg)
